The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2016 | The importance of the Phase III JAVELIN LUNG 100 trial in non-small-cell lung cancer
Martin Reck, MD, PhD of the LungenClinic Grosshansdorf, Grosshansdorf, Germany, highlights the importance of the randomized Phase III JAVELIN Lung 100 trial in non-small-cell lung cancer (NSCLC) (NCT02576574). This trial is investigating the new immune checkpoint inhibitor, the programmed death-1 receptor ligand (PD-L1), avelumab, compared to platinum-based chemotherapy in patients with metastatic or recurrent PD-L1-positive NSCLC who have never been treated before. This is an on-going trial and results are expected in early 2017. Finally, he mentions that the primary endpoint is progression-free survival (PFS) and further, they will look at overall survival (OS), tumor response and tolerability, which is crucial for patients with NSCLC. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
